Economic analyses in haemophilia care are at present limited, but are increasingly being used to examine the costs and outcomes associated with various treatment regimens. The assignment of probabilities and costs in these models can be challenging, and the use and development of new quality-of-life instruments for haemophilia have yet to be fully investigated. These methodological issues need to be addressed to expand research in the area of the economics of haemophilia care.